Hi Analyst007, you mentioned how Clinuvel can benefit from rate hikes and you are definitely correct. For the latest half yearly CUV banked $3.66M in interest to 31/12/23 (compared to $1.33M to 31/12/22). Last full year results $3.9 Million Interest and I'm guessing this year full year will be ~$5 Million EXTRA in interest so maybe banking ~$9 Million plus. So right there is some growth just from the enormous cash pile and that pile will be pushing towards $200 Million by now.
Also as we know Clinuvel competitors have gone backwards this year so the CUV EPP monopoly position is better than ever right now and will continue for many years (the competitors may never enter the EPP market who knows). From a recent newsletter: "We are also seeing new patient and physician demand following conclusion of experimental therapy clinical and expanded access programs.". So a very decent pool of EPP patients seeking treatment are now available for Clinuvel to scoop up, I reckon there is still some growth to come from EPP.
As for growth last year Clinuvel delivered pretty amazing 47% NPAT growth to a very respectable $30.6 Million profit figure. I don't think anyone expects that growth this year but I think there will be some growth IMO and remember CUV is definitely not priced for perfection as PME and so many others are. Clinuvel has moved one year closer since last year to completing their Phase 3 into blockbuster Vitiligo which is slated for 2026 FDA submission with an already approved drug. Shorters have massively increased their position in the last 12 months from 3% open shorts to 6% open shorts in CUV which has nicely pushed the price down and kept it down presenting great buying opportunities for investors and the company itself via the buyback. We saw very strong evidence of the shorters game after the Clinuvel share buyback was announced and shorters pumped in 500000 fake liquidity Sell shares in just days to stop the share price rocketing up and exposing their position.
We just need Clinuvel to do what they said and buyback those 1.5 Million shares in a capital redistribution to shareholders.
All IMO DYOR
- Forums
- ASX - By Stock
- CUV
- Taco shop worth more than Clinuvel
Taco shop worth more than Clinuvel, page-21
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$13.79 |
Change
0.290(2.15%) |
Mkt cap ! $690.5M |
Open | High | Low | Value | Volume |
$13.50 | $13.98 | $13.40 | $1.675M | 122.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 250 | $13.76 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.89 | 57 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 250 | 13.760 |
2 | 416 | 13.690 |
1 | 416 | 13.670 |
4 | 2485 | 13.650 |
1 | 416 | 13.630 |
Price($) | Vol. | No. |
---|---|---|
13.890 | 57 | 1 |
13.900 | 1000 | 1 |
13.910 | 416 | 1 |
13.930 | 416 | 1 |
13.960 | 2008 | 4 |
Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online